Cerebrovascular Disease and Stroke Program recognized by U.S. News & World Report for 2021-2022
Dartmouth-Hitchcock Medical Center is rated as high performing in stroke by U.S. News & World Report in 2021-2022.
Cerebrovascular diseases are disorders of blood vessels and brain arteries that supply blood to the brain. Cerebrovascular diseases can cause common conditions, such as aneurysms, dementia, and strokes, affecting more than 62 million people in the United States.
This website provides information about prevention, recognizing the warning signs of a stroke, and the Cerebrovascular Disease and Stroke Program's methods to diagnose and treat cerebrovascular diseases. We suggest the following links to get you started:
- About our program
- Common conditions and treatments
- Five Things You Need to Know About Stroke (PDF)
- Learning About Stroke: A Guide for Patients and Families (PDF)
Stroke Support Group
A stroke can be a life-changing experience. Not just for the stroke survivor, but for the whole family.
We invite stroke survivors, family members and caregivers to come share their experiences and gain support, education and encouragement from others who know just what you are going through.
Dartmouth-Hitchcock Aging Resource Center
46 Centerra Parkway
Lebanon, NH 03756
First Friday of every even-numbered month
10:00 to 11:30 am
Kindly note that current sessions are virtual due to the current public health concern.
For more information, please contact:
Sarah Braginetz, BS
Stroke Program, Administrative Assistant
Shawna Malynowski, MBA, BSN, RN
Stroke Program Coordinator
Aging Resource Center
About the program
The goal of the Cerebrovascular Disease and Stroke program is to provide the highest quality, evidenced-based care for patients and families dealing with stroke, transient ischemic attack, and other cerebrovascular conditions, including brain aneurysms and vascular malformations.
Specific goals for our program include:
- Becoming recognized as a comprehensive center for cerebrovascular care and the regional "hub" of a stroke network that shares resources and improves access to high-quality and cost-effective care for patients in our region
- Participating in the best clinical trials in our field
- Bringing relevant basic science and translational research to DHMC
- Being a resource for the education of residents, medical students, nurses, primary care providers, and other specialists
The Cerebrovascular Disease and Stroke Program members strive to meet the needs of stroke patients and their caregivers across the entire continuum of care. We aim to decrease the occurrence of stroke and its complications in the population we serve and advance the field of Cerebrovascular disease care.
Program certifications and awards
Joint Commission Certified Primary Stroke Center
The Stroke Program at Dartmouth-Hitchcock Medical Center has attained advanced certification by The Joint Commission. This means that this program:
- Provides the next generation of stroke care
- Has met and seeks to maintain The Joint Commission’s high standards in providing stroke care
The Joint Commission is an independent, not-for-profit organization that accredits and certifies nearly 21,000 health care organizations and programs nationwide.
American Heart Association/American Stroke Association’s Get With The Guidelines®-Stroke Gold Plus Achievement Award
This award is given to health care facilities that meet specific quality achievement measures for the diagnosis and treatment of stroke patients at a set level for a designated period. These measures include evaluation of the proper use of medications and other stroke treatments aligned with the most up-to-date, evidence-based guidelines with the goal of speeding recovery and reducing death and disability for stroke patients. Before discharge, patients should also receive education on managing their health, get a follow-up visit scheduled, as well as other care transition interventions.
American Heart Association/American Stroke Association’s Target: Stroke Elite Plus Honor Roll
To qualify for this recognition, hospitals must meet quality measures developed to reduce the time between the patient’s arrival at the hospital and treatment with the clot-buster tissue plasminogen activator, or tPA, the only drug approved by the U.S. Food and Drug Administration to treat ischemic stroke.